Prospective study of Merkel cell polyomavirus and risk of Merkel cell carcinoma

Merkel cell carcinoma (MCC) is a rare type of skin cancer that has a characteristically increased incidence among immunosuppressed subjects. The DNA of Merkel cell polyomavirus (MCV) is regularly found in most MCC tumors. We investigated whether Merkel cell polyomavirus (MCV) infection increases the risk for future MCC. Two large biobank cohorts (Southern Sweden Microbiology Biobank and the Janus Biobank), containing samples from 856,000 healthy donors, were linked to the Cancer Registries in Sweden and Norway to identify cases of MCC occurring up to 30 years after donation of a serum sample. For each of the 22 cases (nine males and 13 females), four matched controls were included. The serum samples were analyzed with an MCV neutralization assay and for IgG antibodies to MCV pseudovirions, using JC polyomavirus and cutaneous human papillomaviruses as control antigens. An increased risk for future MCC was associated both with high levels of MCV antibodies [OR 4.4, 95% CI 1.3–17.4] and with MCV neutralizing activity (OR 5.3, 95% CI 1.3–32.3). In males, MCV seropositivity was not associated to MCC risk, whereas the risk was strongly increased in females, both for high levels of MCV antibodies (OR 7.0, 95% CI 1.6–42.8) and for MCV neutralizing activity (OR 14.3, 95% CI 1.7–677). In conclusion, we found prospective evidence that MCV infection is associated with an increased risk for future MCC, in particular among females.

[1]  K. Straif,et al.  Carcinogenicity of malaria and of some polyomaviruses. , 2012, The Lancet. Oncology.

[2]  K. Hayashi,et al.  Association of Merkel cell polyomavirus infection with clinicopathological differences in Merkel cell carcinoma. , 2011, Human pathology.

[3]  F. Wiklund,et al.  Prospective Seroepidemiologic Study of Human Papillomavirus and Other Risk Factors in Cervical Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[4]  S. Kuwamoto Recent advances in the biology of Merkel cell carcinoma. , 2011, Human pathology.

[5]  H. Pfister,et al.  Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer , 2011, Medical Microbiology and Immunology.

[6]  P. Coursaget,et al.  High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Dillner,et al.  Antibodies to Merkel cell polyomavirus correlate to presence of viral DNA in the skin. , 2011, The Journal of infectious diseases.

[8]  O. Visser,et al.  Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993-2007. , 2011, European journal of cancer.

[9]  F. Bray,et al.  Risk of second cancers after the diagnosis of Merkel cell carcinoma in Scandinavia , 2010, British Journal of Cancer.

[10]  K. Hayashi,et al.  Association of Merkel cell polyomavirus infection with morphologic differences in Merkel cell carcinoma. , 2011, Human pathology.

[11]  D. Galloway,et al.  Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. , 2010, Cancer research.

[12]  Nicolas Dupin,et al.  Distinct Merkel Cell Polyomavirus Molecular Features in Tumour and Non Tumour Specimens from Patients with Merkel Cell Carcinoma , 2010, PLoS pathogens.

[13]  J. Dillner,et al.  Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. , 2010, The Journal of general virology.

[14]  C. Buck,et al.  Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. , 2010, Cell host & microbe.

[15]  J. Molès,et al.  Merkel Cell Polyomavirus in Cutaneous Swabs , 2010, Emerging infectious diseases.

[16]  P. Coursaget,et al.  Generation of Merkel Cell Polyomavirus (MCV)-Like Particles and Their Application to Detection of MCV Antibodies , 2010, Journal of Clinical Microbiology.

[17]  Joakim Dillner,et al.  Ensuring quality in studies linking cancer registries and biobanks , 2010, Acta oncologica.

[18]  D. Henson,et al.  Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study , 2010, Journal of cutaneous pathology.

[19]  J. Goedert,et al.  Immunological detection of viral large T antigen identifies a subset of Merkel cell carcinoma tumors with higher viral abundance and better clinical outcome , 2009, International journal of cancer.

[20]  D. Galloway,et al.  Association of Merkel Cell Polyomavirus–Specific Antibodies With Merkel Cell Carcinoma , 2009, Journal of the National Cancer Institute.

[21]  T. Schulz Cancer and viral infections in immunocompromised individuals , 2009, International journal of cancer.

[22]  J. Becker,et al.  Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays , 2009, International journal of cancer.

[23]  J. Becker,et al.  Quantitation of Human Seroresponsiveness to Merkel Cell Polyomavirus , 2009, PLoS pathogens.

[24]  H. Joensuu,et al.  Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. , 2009, Journal of the National Cancer Institute.

[25]  R. Garcea,et al.  Seroepidemiology of Human Polyomaviruses , 2009, PLoS pathogens.

[26]  B. Thiers,et al.  Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma , 2009 .

[27]  Pär Stattin,et al.  Nordic biological specimen banks as basis for studies of cancer causes and control – more than 2 million sample donors, 25 million person years and 100 000 prospective cancers , 2007, Acta oncologica.

[28]  J. Dillner,et al.  Subtype HPV38b[FA125] demonstrates heterogeneity of human papillomavirus type 38 , 2006, International journal of cancer.

[29]  D. Lowy,et al.  Efficient Intracellular Assembly of Papillomaviral Vectors , 2004, Journal of Virology.

[30]  Joakim Dillner,et al.  Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. , 2002, Journal of immunological methods.

[31]  F. Vogel,et al.  Yeast Cells Allow High-Level Expression and Formation of Polyomavirus-Like Particles , 1999, Biological chemistry.

[32]  R. Peto,et al.  Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study , 1996, BMJ.